072 Five-year outcome of patients with bifurcation lesions treated with provisional side branch T-stenting using drug-eluting stents  by Salvatella, Neus et al.
© Elsevier Masson SAS. All rights reserved.
 
Archives of Cardiovascular Diseases Supplements (2011) 3, 1-25 23
Results: 979 Pts (63.2 ± 11.6 years, 87.3% male) were studied. Baseline
demographics and angiographic characteristics were similar between groups
with no difference in lesion length, calcification or proximal vessel tortuosity.
There was a significant difference in the rate of bifurcations performed via the
TRA and TFA (29.1% vs. 14.6%, p<0.0001). Parallel wire technique and ret-
rograde recanalisation were used more frequently from the TFA. TRA was
associated with an increased use of anchoring balloons.
Sheath sizes > 6 French were used in 20/979(2%). Larger sheath size was
associated with a higher rate of parallel wire technique (p=0.0004), retrograde
recanalisation (p<0.0001) and tornus use (p=0.027). 
Conclusions: TRA has equivalent success rates to TFA in Pts with similar
lesion characteristics, requires less invasive sheath sizes and allows complex
techniques such as retrograde recanalisation.
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Background: Drug–eluting stents (DES) are known to dramatically reduce
restenosis. However, they are more expansive than bare-metal stents (BMS)
and they require prolonged dual antiplatelet therapy. In France, the French
Society of Cardiology and the “Haute autorité de Santé” have defined recom-
mendations for the use of DES (restricted to patients in high-risk group). 
Aim: The aim of this work was to evaluate our practice (whether these rec-
ommendations were well respected or not in our center). Between November
2007 and January 2008 then November 2008 and January 2009 we evaluated
all Percutaneous Coronary Interventions (PCI).
Results: Two hundred and sixteen (216) patients (mean age 65 ± 13 years,
164 (76 %) were males and, 41 (19%) were diabetics) had a PCI for stable
angina or silent ischemia (47%), unstable angina or acute coronary syndrome
(ACS) ST- (26%), ACS ST+ < 48 hours (24%) or ACS ST+ > 48 hours-1
month (3%). Two hundred and seventy six (276) stents were used, including
35% of DES. The recommendations were well respected in 82% of cases.
However, 27% of BMS were implanted in patients in whom DES were indi-
cated. 
Conclusion: The French’s recommendations for DES are a reference to
help practitioners, but they require to be adapted to each patient, depending on
clinical state and their ability to be treated with prolonged dual antiplatelet
therapy.
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Background: Coronary bifurcation lesions remain a challenge, as lower
success rates and higher reintervention rates persist in this lesion subset. The
ideal strategy to treat such lesions is still debated and data regarding long-term
efficacy and safety of drug-eluting stents in this setting are sparse. 
Objectives: We sought to determine the long-term efficacy and safety of a pro-
visional side branch T-stenting (PTS) strategy for bifurcation lesions in an
unselected population.
Methods: 477 consecutive Pts were treated for bifurcation lesions with
DES (Paclitaxel or Sirolimus-eluting stents) between 2003 and 2005. Data
were entered prospectively into a single-center registry. The PTS strategy was
employed in 92%, with a side-branch stent in 28% and final kissing balloon
inflation in 95%. Five-year follow-up, at a median of 61 months, is available
for 93.5 % of patients.
Results: Angiographic success was achieved in 99%, with 2.5 % in-hos-
pital major adverse cardiac events (MACE, defined as any cardiac death, early
reintervention, Q – or non-Q-wave MI or target vessel revascularisation). The
cumulative rate of MACE was 10.7 % at 1 year, 13.6% at 2 years and 19.7%
at 5 years, including target vessel revascularisation rates of 6.9%, 8.9% and
13%, and cardiac death rates of 3%, 3.7% and 6.7%, respectively. Ischaemia-
driven target lesion revascularisation at 5 years is 7.3%. The cumulative rate
of definite or probable stent thrombosis at long-term is 3.1%, most cases
occurring within the first year (2.5%). The need for reintervention in the long-
term was not predicted by any procedural variable, and not significantly
related to the use of 1 or 2 stents or to the type of stent deployed.
Conclusions: A PTS strategy with first generation drug-eluting stents, was
applicable to over 90% of real-world patients with bifurcation lesions with a
target lesion revascularisation < 10% at 5 years. The rate of very-late stent
thrombosis in this complex lesion subset remains low.
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Purpose: Antiplatelet drugs, including aspirin and clopidogrel have proven
efficacy in atherothrombotic event prevention. However, variability of platelet
response measured in the laboratory has been reported and is a subject of keen
interest. 
Methods: 500 consecutive Pts treated with PCI between Nov 2007 and
Dec 2009 and who had VASP and PFA tests performed were retrospectively
identified from a dedicated database. All Pts were pretreated with a loading
dose of 600mg clopidogrel and had a daily maintenance dose of 75mg, or
150mg if their weight was > 80kg. All Pts were under regular aspirin (160mg/
day). Using VASP >50% and PFA<170 to define aspirin and clopidogrel resis-
tance, we compared Pts who were double non-responders with double
responders.
Results: 246 (49.2%) patients were responders to both aspirin and clopi-
dogrel, while 58 (11.6%) were double non-responders. Multivariate analysis
confirmed statistical significance between hypertensive Pts and double
 TFA (233 patients) TRA (646 patients)P value
Sheath size – 6F 218 (93.6%) 642 (99.4%) <0.0001
Sheath size – 8F 11 (4.7%) 0 (0) <0.0001
Parallel wire 54 (23.2%) 106 (16.4%) 0.029
Side branch technique 7 (3.0%) 41 (6.3%) 0.06
Anchoring balloon 7 (3.0%) 48 (7.4%) 0.017
Retrograde recanalisation 16 (6.9%) 18 (2.8%) 0.009
Procedural time 73.4 +/–41.2min 80.7+/–40.7min 0.03
Contrast use 238.7mls +/–180.2mls 286.2 +/–157.3mls 0.001
Angiographic Success 139 (67.8%) 441 (70.7%) 0.44
